BioSyent Inc.
RX.V
Get informed when a big investor buys or sells
+ FollowMarket Cap$196.17M
Close$
$17.28
0.7% upside
Current Fair Value
0.7% upsideUndervalued by 0.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $196.17 Million |
|---|---|
| Enterprise Value | $194.42 Million |
| Dividend Yield | $0.21 (1.25%) |
| Earnings per Share | $0.8 |
| Beta | 0.6 |
| Outstanding Shares | 11,393,271 |
Return
| Return on Equity | 21.53% |
|---|---|
| Return on Assets | 16.32% |
| Return on Invested Capital | 28.19% |
Valuation & Multiples
| P/E Ratio | 19.49 |
|---|---|
| PEG | 47.32 |
| Price to Sales | 4.29 |
| Price to Book Ratio | 4.29 |
| Enterprise Value to Revenue | 3.49 |
| Enterprise Value to EBIT | 14.78 |
| Enterprise Value to Net Income | 19 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$17.60 M
Average shareholder expectationNext Earnings Call
Expected Date
November 19, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$19.50 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BioSyent Inc.
711 employees
CEO: René C. Goehrum BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iro...